Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Growth-inhibitory effects of the chemopreventive agent indole-3-carbinol are increased in combination with the polyamine putrescine in the SW480 colon tumour cell line

  • E Ann Hudson1Email author,
  • Lynne M Howells1,
  • Barbara Gallacher-Horley2,
  • Louise H Fox1,
  • Andreas Gescher3 and
  • Margaret M Manson1
BMC Cancer20033:2

DOI: 10.1186/1471-2407-3-2

Received: 8 July 2002

Accepted: 14 January 2003

Published: 14 January 2003

Abstract

Background

Many tumours undergo disregulation of polyamine homeostasis and upregulation of ornithine decarboxylase (ODC) activity, which can promote carcinogenesis. In animal models of colon carcinogenesis, inhibition of ODC activity by difluoromethylornithine (DFMO) has been shown to reduce the number and size of colon adenomas and carcinomas. Indole-3-carbinol (I3C) has shown promising chemopreventive activity against a range of human tumour cell types, but little is known about the effect of this agent on colon cell lines. Here, we investigated whether inhibition of ODC by I3C could contribute to a chemopreventive effect in colon cell lines.

Methods

Cell cycle progression and induction of apoptosis were assessed by flow cytometry. Ornithine decarboxylase activity was determined by liberation of CO2 from 14C-labelled substrate, and polyamine levels were measured by HPLC.

Results

I3C inhibited proliferation of the human colon tumour cell lines HT29 and SW480, and of the normal tissue-derived HCEC line, and at higher concentrations induced apoptosis in SW480 cells. The agent also caused a decrease in ODC activity in a dose-dependent manner. While administration of exogenous putrescine reversed the growth-inhibitory effect of DFMO, it did not reverse the growth-inhibition following an I3C treatment, and in the case of the SW480 cell line, the effect was actually enhanced. In this cell line, combination treatment caused a slight increase in the proportion of cells in the G2/M phase of the cell cycle, and increased the proportion of cells undergoing necrosis, but did not predispose cells to apoptosis. Indole-3-carbinol also caused an increase in intracellular spermine levels, which was not modulated by putrescine co-administration.

Conclusion

While indole-3-carbinol decreased ornithine decarboxylase activity in the colon cell lines, it appears unlikely that this constitutes a major mechanism by which the agent exerts its antiproliferative effect, although accumulation of spermine may cause cytotoxicity and contribute to cell death. The precise mechanism by which putrescine enhances the growth inhibitory effect of the agent remains to be elucidated, but does result in cells undergoing necrosis, possibly following accumulation in the G2/M phase of the cell cycle.

Background

There is strong epidemiological evidence to support a protective role of fruit and vegetables against the development of cancer in a range of major organs, in particular of the breast and the digestive tract. This evidence has led to the isolation and characterisation of discreet dietary constituents that may be responsible for their chemopreventive activity. I3C is derived from cruciferous vegetables such as broccoli and Brussels sprouts, and possesses anticarcinogenic activity in a number of models, both in vivo and in vitro. It has received considerable attention as a potential anti-tumour agent for breast cancer, particularly due to its ability to alter the estrogen metabolite ratio of 2-hydroxyestrone to 16-α-hydroxyestrone [13], and has recently been the subject of a breast cancer prevention dose-finding pilot study using the urinary estrogen metabolite ratio as the surrogate endpoint biomarker [4]. Promising results have been obtained in phase I clinical trials of I3C against recurrent respiratory papillomatosis or cervical intraepithelial neoplasia [5, 6].

I3C has also been shown to protect against carcinogen-induced tumours in a range of rodent models including liver, tongue, skin, mammary tissue and colon [712]. Some studies however, have suggested that when administered after chemically-induced initiation, I3C may have promoting activity in liver, raising concerns as to its suitability for use as a chemopreventive agent in humans [1215]. The latter two of these studies showed that in medium and long-term treatment protocols (10 and 30 weeks respectively), I3C increased glutathione S-transferase-P (GST-P) positive foci in livers of rats initiated with diethylnitrosamine [15], or in a multi-organ rat model initiated with 7,12-Dimethylbenz [a]anthracene plus azoxymethane plus AFB1 [12], and these results were interpreted as indicating a promoting effect of I3C on hepatocarcinogenesis. In a long-term (48 week) feeding study we showed that I3C prevented aflatoxin B1 (AFB1)-induced liver carcinogenesis in Fisher F344 rats, irrespective of whether it was administered before or after the carcinogen [7]. Interestingly, at an earlier time point in our feeding study (13 weeks) we observed strong focal liver staining for γ-glutamyl transpeptidase and GST-P in rats treated with I3C post-initiation. Using these criteria alone as predictors of tumourigenesis, we would have expected no effect, or indeed an increase in tumours in the livers of these animals. However this was not the case, and at 48 weeks the animals treated with I3C following AFB1 were completely protected [7]. While the mechanism by which I3C exerts tumour blocking activity has been attributed to the induction of drug metabolising enzymes, which can lead to increased conjugation and excretion of the carcinogen and decreased DNA adduct formation [1623], the mechanisms by which it suppresses tumour promotion and progression are not well defined.

Inhibition of ornithine decarboxylase (ODC) activity has been proposed as a target mechanism for tumour suppression, reviewed by Pegg [24]. ODC is the rate-limiting enzyme in the biosynthesis of polyamines, which are required for normal cell proliferation. Polyamine levels and ODC activity are elevated in a wide range of tumours, and high levels correlate with poor prognosis in breast cancer patients [2527]. ODC has further been implicated in the carcinogenic process by findings that overexpression promotes tumourigenesis in vivo, and can be sufficient for transformation of cell lines in vitro [2831]. Therefore inhibition of ODC activity has been commonly used as a predictor of chemopreventive activity, and as an intermediate endpoint biomarker of clinical efficacy in intervention studies. The regulation of ODC activity within the cell is complex, and occurs at a multitude of levels, [3234], including protein degradation, post-translational modification, mRNA translation and gene transcription. ODC protein levels are regulated by antizyme, which binds to, and targets ODC for degradation by the 26S proteasome, reviewed in [35]. ODC is also heavily regulated at the level of mRNA translation due to secondary structure in the 5' untranslated region, which can be modified by activity of the translation initiation factor eIF-4E [32, 36]. The ODC promoter has been shown in various species to be regulated by a number of transcription factors, including the Wilms' tumour suppressor WT1 [3740] and references therein. ODC activity can also be modulated in response to many signalling pathways including the epidermal growth factor receptor, phospho-inositide 3-kinase (PI3K), and estrogen receptor pathways [4144].

In the long term feeding study mentioned above [7], the level of ODC activity in livers of rats which received dietary I3C was markedly decreased compared to that in rats on a control diet. The current study was designed to explore whether alteration of ODC activity and polyamine levels might play a mechanistic role in the chemopreventive efficacy of I3C in colon cells. To that end the effects of I3C on cell growth, ODC activity and intracellular polyamine levels were studied in human-derived colon cancer cells.

Difluoromethylornithine (DFMO) is a well-studied specific inhibitor of ODC enzyme activity. Initial trials of DFMO as a cancer therapeutic agent were disappointing, showing dose-limiting toxicity, together with little therapeutic activity. The contents of the intestinal and colonic lumen form a rich supply of polyamines, augmented by dietary sources and intestinal bacteria [4549]. Exogenous polyamines are rapidly taken up by polyamine-depleted cells, and can be utilised for tumour growth [50], offering one explanation for the apparent lack of activity of DFMO in humans. However, more recently, DFMO has attracted much interest as a potential chemopreventive agent at lower doses [5158].

In order to determine any similarity in mechanism of chemopreventive activity between I3C and DFMO the modulation of the growth inhibitory effects of the two agents by polyamines was investigated.

Methods

Cell lines and treatments

Immortalized human colon epithelial cells (HCEC) and human-derived colon carcinoma cell lines SW480 and HT29 were kindly provided by A. Pfeifer (Nestec Ltd., Lausanne, Switzerland) and C. Paraskeva (Bristol University, UK), respectively, and were cultured as described previously [59, 60]. All cell lines tested negative for mycoplasma infection and were cultured without antibiotics. I3C (Sigma-Aldrich Company Ltd.; Poole, UK) was prepared as a stock solution in DMSO, and cells were treated in such a way that all control and treated cells received equal volumes of DMSO, which did not exceed a final concentration of 0.05%. For each experiment, cells were seeded in normal growth medium and were allowed to adhere for at least 4 hours before treatment. Cells were treated with concentrations of I3C from 100 μM up to 1 mM in some experiments. It should be noted that any effects seen at concentrations above 500 μM are unlikely to be physiologically relevant. All cell culture reagents (GIBCO) were purchased from Invitrogen Ltd. (Paisley, UK).

Cell growth assays

Cells were seeded at 1 × 104 onto 24 well plates in normal growth medium, and allowed to adhere, prior to treatment with I3C for times up to 10 days. The culture medium was not changed during the incubation time. Cells were harvested by trypsinisation at 24 hourly intervals and counted on a Coulter ZM electronic cell counter (Beckman Coulter UK Ltd., High Wycombe, UK).

Mean IC50 values were obtained from plots of cell number expressed as a percentage of control, versus I3C concentration following treatment for 7 days. In further growth experiments, HT29 and SW480 cells were treated with concentrations of I3C (250 or 175 μM respectively), or DFMO (125 or 50 μM; CN Biosciences (UK) Ltd., Beeston, UK), and cultured for 7 days in the presence or absence of putrescine as indicated. To determine their ability to recover proliferative capacity following treatment, cells (1 × 104 on 12 well plates) were cultured in the presence of I3C, plus or minus putrescine, for 24 hours, after which they were either maintained in treated medium or washed and replenished with fresh medium and allowed to recover before harvesting on day 7. The proliferation rate of cells was calculated as fold increase in cell number following the initial treatment period.

For analysis of cell cycle, 5 × 105 cells were seeded onto 9 cm plates and treated with I3C in the presence or absence of putrescine for 96 hours. Cells were harvested by trypsinisation and fixed overnight in 70% ethanol at 4°C, then collected by centrifugation and resuspended in PBS containing 0.1 mg/ml RNase and 5 μg/ml propidium iodide and incubated overnight at 4°C. DNA content was analysed using a Becton Dickinson FACScan and Cell Quest software, plotting 5000 events per sample. Subsequent data analysis was performed using ModFit LT software (Becton Dickinson UK Ltd.; Cowley, UK).

Measurement of phosphatidylserine externalisation

Cells were seeded at 2–5 × 105 onto 9 cm plates and treated with I3C for 96 hours. After treatment, cells obtained by trypsinisation were combined with those that had spontaneously detached during the incubation. Phosphatidylserine externalisation was determined by annexin V staining. Cells were pelleted and resuspended in 1 ml annexin buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2). FITC-conjugated annexin V was added to a final concentration of 100 ng/ml and cells were incubated for 8 min at room temperature, after which propidium iodide (1.5 μg) was added and cells were analysed by flow cytometry using a FACScan flow cytometer (Becton Dickinson, San Jose, CA) and Cell Quest software.

Measurement of ODC activity

Colon cells were seeded at 5 × 105 onto 9 cm plates and allowed to adhere prior to treatment with I3C for 24 hours. Whole cell lysates were prepared by successive rounds of freeze thawing of cells suspended in 200 μl sodium phosphate buffer (100 mM, pH 7.2). ODC activity in cell lysates (90 μl) was determined by measurement of 14CO2 released from labelled ornithine, under reaction conditions described previously [7]. Protein content of cell lysates was determined using the BioRad protein assay kit (Bio-Rad Laboratories Ltd., Hemel Hempstead, UK). ODC activity was calculated as pmol CO2 produced/ mg protein/ hour, and results are expressed as a percentage of activity in control samples (DMSO-treated).

Measurement of intracellular polyamine levels

Cells seeded onto 9 cm plates at densities between 5 × 105 and 2 × 106 depending on treatment time, were treated with I3C in the presence or absence of putrescine for 24, 96 or 168 hours, and were then harvested and washed twice with PBS. Cell pellets were resuspended in 200 μl 10% trichloroacetic acid, and the acid-soluble polyamines extracted by centrifugation. Dansylated polyamines were detected by fluorescence, following separation by ion-pairing reversed phase HPLC. Dansylation and extraction of polyamines was based on published methods [61, 62]. In brief, extracts were mixed with 400 μl dansyl chloride (5 mg/ml in acetone) in the presence of approximately 300 mg solid sodium carbonate, together with 500 nmol of the internal standard 1,6-hexanediamine, and incubated for 20 min at 70°C. Reactions were allowed to cool to room temperature and excess dansyl chloride was sequestered by the addition of 200 μl proline (250 mg/ml). Polyamines were then extracted into 4 ml cyclohexane, and following evaporation of the cyclohexane were reconstituted in 200 μl acetonitrile. Dansylated polyamines were separated and detected using a Gilson 715 series HPLC system with a BDS C18 column (250 × 4.6 mm, particle size 3 μm, Hypersil, Runcorn, UK) coupled to a Waters 470 scanning fluorescence detector (excitation 336 nm, emission 520 nm). The mobile phase consisted of a gradient between buffer A (0.02 M 1-heptanesulphonic acid (pH 3.4), acetonitrile, methanol (5:3:2 v/v)) and buffer B (acetonitrile, methanol (3:2 v/v)) essentially as described by Aboul-Enein and Al-Duraibi [63].

Measurement of putrescine uptake

SW480 cells were seeded at 5 × 104 onto 24 well plates, and treated with I3C (0–500 μM) or DFMO (50 μM) in 1 ml medium for 24 hours. Cells were then treated with 10 μl 10 mM putrescine containing 0.25 μCi 14C-labelled putrescine, and incubated for a further 30 min prior to termination of the experiment. Cells were then washed thoroughly with 1 mM putrescine, and lysed in 250 μl 1 M NaOH 60°C for 1 hour. The lysate was neutralised with 250 μl 1 M HCl, and 14C-labelled putrescine that had been incorporated into the cells was determined by scintillation counting. Protein content of the lysates was determined using the BioRad protein assay reagent.

Measurement of intracellular glutathione

Cells were seeded at 5 × 104 to 1 × 106 onto 6 well plates (according to treatment time) and treated with I3C in the presence or absence of putrescine for 24, 96 or 168 hours. Cells were harvested by trypsinisation and intracellular glutathione levels were determined according to the method of Baker et al. [64].

Statistical analysis

Data were analysed by ANOVA using either Oneway analysis followed by Tukey's posthoc test, or the General Linear Model twoway analysis followed by Fisher's Least Significant Difference test, as appropriate [65, 66].

Results

Effect of I3C on proliferation and ODC activity of colon cell lines

I3C inhibited proliferation of the two tumour-derived colon cell lines SW480 and HT29, and of the normal-derived HCEC cell line (Fig 1). The IC50s (mean ± SD, n = 3; 168 hr) for the SW480, HT29 and HCEC cell lines were calculated as 123.22 ± 8.87; 127.20 ± 8.13 and 164.5 ± 7.0 μM respectively. These values are consistent with concentrations reported to exert biological activity in a range of other cell lines [6770]. The basal level of ODC activity was low in the normal-derived HCEC line, 156.1 ± 9.3 pmol CO2 produced/ hour/ mg protein, while levels were found to vary markedly between the two tumour cell lines. The HT29 line showed high activity, 1079.0 ± 42.4, while the SW480 line exhibited activity of 171.3 ± 20.9 pmol CO2 produced/ hour/ mg protein. The SW480 cell line is unusual in this respect, as tumour derived cell lines commonly exhibit high levels of ODC activity. I3C decreased basal ODC activity in a dose-dependent manner in all three colon cell lines after treatment for 24 hours (Fig 2), with the HCEC line showing greatest sensitivity, and the SW480 line showing least inhibition. I3C did not inhibit ODC activity when the agent was added directly into an assay (data not shown), indicating that the agent does not act as a direct enzyme inhibitor. Interestingly, the HCEC cell line showed the least decrease in cell number in response to I3C at this time point. This lack of apparent cytotoxicity is in agreement with a recent study by Bonnesen et al. [71], which reported an IC50 in excess of 500 μM I3C in this cell line using MTT tests carried out after 24 hours.
Figure 1

Inhibition of cell growth by I3C. Cells were treated with I3C and counted at 24 hourly intervals as described in Materials and Methods. Results are presented as mean ± SEM (n = 6), * indicates significant difference from control cell numbers at that time point (P < 0.05).

Figure 2

Effect of I3C on basal ODC activity and cell number after 24 hours. ODC activity in cell lysates was determined as described in Materials and Methods. Results are expressed as a percentage of control values (n = minimum of 5; pooled SD of each set for ODC activity and cell number for each cell line are: SW480, 18.76, 11.38; HT29, 13.12, 4.11; HCEC, 15.22, 12.37 respectively). Significant difference from the control (DMSO treated) is indicated by * (P < 0.05).

Effect of exogenous putrescine on growth modulation by DFMO and I3C

To determine the extent to which inhibition of ODC activity contributed to the antiproliferative activity of I3C in the tumour lines, we made a comparison of its growth inhibitory effect with that of the specific ODC inhibitor, and known antitumour agent, DFMO. The growth inhibitory action of DFMO can be reversed by exogenously added putrescine, which restores intracellular levels of polyamines required for cell proliferation. In all three cell lines, supplementation of culture medium with putrescine reversed the effects of DFMO as expected, and in agreement with data obtained for the HT29 cell line by Gamet et al. [72]. We hypothesised therefore that if the growth-inhibitory effect of I3C was directly related to its ability to decrease ODC activity, then as for DFMO, this may be reversed by supplementation with putrescine. Interestingly, putrescine did not reverse the inhibitory effect caused by I3C in any of the colon cell lines, and at concentrations that did not affect control cell growth (5–100 μM), it actually increased growth inhibition of I3C-treated SW480 cells in a dose-dependent manner (Fig. 3; p < 0.05). This cell line was also found to be particularly sensitive to exogenously added putrescine, with concentrations in excess of 100 μM inhibiting proliferation of control cells. In contrast, the HT29 and HCEC cell lines were resistant to concentrations of exogenous putrescine up to 500 μM, whether cultured with or without I3C.
Figure 3

Effect of putrescine supplementation on cell growth inhibition by I3C and DFMO. Cells were treated with I3C (SW480 175 μM; HT29 250 μM; HCEC 180 μM) or DFMO (SW480 50 μM; HT29 and HCEC 125 μM) or DMSO (control) and cultured in the presence or absence of putrescine (5–500 μM) for 7 days and then counted as described in Materials and Methods. Results are mean ± SD (n = 4), a indicates bars which are significantly different from control (DMSO without putrescine) group, b indicates significant difference from the I3C alone treatment, and c indicates significant difference from the DFMO alone treatment (P < 0.05).

The cell lines also differed in their ability to recover from treatment with I3C (Fig 4). The HT29 cell line recovered completely from 24 hour treatment with I3C up to 500 μM, and also recovered from combined I3C (250 μM)/ putrescine (500 μM) treatment. In contrast, SW480 cells only partially recovered from 24 hour treatment with I3C at 175 μM in the presence or absence of putrescine (50 μM), and were unable to recover from higher concentrations of I3C. The HCEC cell line behaved more like the HT29 line, but did not recover completely. The reason for this apparent difference in the ability of the two tumour cell lines to recover from treatment is not clear at the present time. However, these data may suggest that I3C could be acting via different mechanisms, one reversible and one irreversible; alternatively, it is also possible that the effect is time dependent and that treatment with I3C for a longer period would have resulted in irreversible growth inhibition in the HT29 cell line also. We have previously observed a difference in the ability of two breast cell lines, HBL100 and MDA MB468 to recover from I3C treatment [67], which we concluded was related to the induction of apoptosis in the latter, but not in the former cell line.
Figure 4

Recovery of cells from 24 hour treatment with I3C. Cells were cultured in the presence of I3C for 24 hours, after which cells were either maintained in I3C-containing medium or replenished with fresh medium and allowed to recover, as described in Materials and Methods. Cell proliferation is expressed as a % of the control values, data are presented as mean ± pooled SD (shown on control bar only; n = 3). Significant difference from the control (DMSO treated) is indicated by * (P < 0.05).

Effect of I3C and exogenous putrescine on induction of apoptosis or cell cycle arrest

In order to investigate whether I3C induces apoptosis in colon cells, and to address the possibility that the combination treatment of I3C plus putrescine may predispose SW480 cells to apoptosis, we compared levels of live, apoptotic and necrotic cells, determined by measurement of phosphatidylserine externalisation after treatment with I3C alone, I3C plus putrescine, or DFMO.

Treatment with I3C caused significant induction of apoptosis in the SW480 cell line at 250 and 500 μM after 96 hour treatment, but only slight induction was apparent with 175 μM (Fig 5). Induction of apoptosis was accompanied by an increase in necrotic cells, possibly due to secondary necrosis of previously apoptotic cells. It seems unlikely that the low level of apoptosis seen in response to 175 μM I3C after 96 hours could account for the apparently irreversible nature of growth inhibition observed for this concentration in the SW480 cell line.
Figure 5

Induction of apoptosis or necrosis in SW480 cells by I3C in the presence or absence of putrescine. Cells were treated for 96 hours and then harvested and stained for phosphatidylserine externalisation and propidium iodide incorporation before analysis by flow cytometry as described in Materials and Methods. Control = DMSO treated cells, C+P = DMSO plus putrescine (50 μM), I175, I250, I500 = I3C (at the given concentration) and I+P = I3C (175 μM) plus putrescine. Significant difference from control is indicated by a, and between the I3C 175 μM and I3C + putrescine treatment by b (P < 0.05). Results are displayed as means (n = 12), pooled SD = 6.08.

The combination treatment did not further induce apoptosis, but did cause a significant increase in the proportion of cells undergoing necrosis (9.5% in the I3C + putrescine treatment compared with 4% for I3C 175 μM alone; P < 0.05). The effect of combination of putrescine with higher concentrations of I3C (250 or 500 μM) was not assessed due to the high level of toxicity encountered with the original combination treatment (I3C 175 μM + putrescine). Putrescine alone had no effect on control cells. DFMO did not induce apoptosis or necrosis following treatment for 96 hours (data not shown).

We also investigated whether cell cycle arrest may contribute to the inhibition of cell growth at these concentrations. DFMO caused an increase in the proportion of cells in G0/G1 phase of the cell cycle in both tumour cell lines, as has been previously reported in other cell lines [7375]. No major phase specific block in cell cycle progression was observed following treatment with I3C alone or in combination with putrescine for 96 hours in either cell line. However, I3C caused a small but significant decrease in G0/G1, which was accompanied by an increase in the proportion of cells in G2/M in the SW480 cell line. Accumulation of cells in G2/M achieved significance in the I3C + putrescine treatment compared with control SW480 cells, but was not significantly elevated above levels of I3C treated cells (Fig. 6A). In order to further investigate this effect, cells were first synchronised in G2/M by treatment with nocodazole, and then released into either control or I3C ± putrescine-treated medium. Neither I3C alone, nor in combination with putrescine caused a delay in exit of cells from G2/M, however, cells in both treatment groups appeared to accumulate in G2/M by 32 hours after release (Fig 6B). The agents did not prolong progression of cells through any phase of the cycle within 24 hours of release from nocodazole block.
Figure 6

Effect of I3C in the presence or absence of putrescine on progression of SW480 cells through the cell cycle. A) Cells were treated for 96 hours as indicated, and stained with propidium iodide before analysis by flow cytometry as described in Materials and Methods. Control = DMSO treated cells, C+P = DMSO plus putrescine (50 μM), I3C = I3C (175 μM) and I+P = I3C (175 μM) plus putrescine, DFMO = DFMO (50 μM). * indicates a significant difference from control levels (P < 0.05; n = 8; pooled SD = 3.54). B) Cells were synchronised with nocodazole for 24 hr (Noc (24 hr)) and then released into control (Con +32 hr), I3C (I3C +32 hr) or I+P (I+P +32 hr) treated medium and analysed as described in Materials and Methods. Data from the +32 hr time point is shown. Control = DMSO treated, non-synchronised cells. * indicates a significant difference from the Con +32 hr value for each phase of the cell cycle (P < 0.05; n = 4; pooled SD = 2.61).

Modulation by I3C of intracellular polyamines and effect of exogenous putrescine in SW480 cells

To investigate whether modulation of intracellular polyamine levels could be contributing to the sensitisation of the SW480 cells to I3C by putrescine, intracellular putrescine, spermidine and spermine levels were measured after treatment with I3C in the presence or absence of putrescine. In control cells at the 24 hour time point, spermine was the most abundant of the polyamines analysed, occurring at levels approximately 1.5 and 4 fold higher than spermidine and putrescine respectively. Exposure to I3C for 24 hr resulted in a significant decrease in intracellular putrescine levels, which was completely reversed by co-exposure of the cells to exogenous putrescine (Fig 7; Table 1). The I3C-induced decrease was transient, as by 96 hours of treatment, intracellular putrescine was found to be slightly raised above control levels. Levels of spermidine were not consistently altered at any time point during exposure to I3C (Table 1). In contrast, at each time point, levels of intracellular spermine were increased in cells treated with I3C concentrations that caused a decrease in cell number (Fig. 8), indicating a possible inverse relationship between spermine accumulation and cell growth. While co-administration of exogenous putrescine restored intracellular putrescine levels to normal, it did not alter intracellular levels of spermine in control cells, or prevent the accumulation of spermine in I3C-treated cells (data not shown). The total intracellular level of the three polyamines was also increased in response to I3C, in a pattern corresponding with that of the major component, spermine.
Figure 7

Effect of I3C in the presence or absence of putrescine on intracellular putrescine levels in SW480 cells following 24 hour treatment. Cells were cultured with DMSO alone (Control) or I3C (175 μM) in the presence of 0, 20 or 50 μM putrescine as indicated. Intracellular putrescine levels were determined by HPLC, as described in Materials and Methods. Results are presented as mean ± pooled SD (shown on control bar only, n = 4). nd = value not determined. Significant difference from the control (DMSO without putrescine), and from I3C without putrescine, is indicated by a and b respectively (P < 0.05).

Figure 8

Effect of I3C on cell number and intracellular spermine levels in SW480 cells after 24, 96 or 168 hour treatments. Cells were treated with DMSO alone (Con) or I3C as indicated, and intracellular spermine levels were determined by HPLC, as described in Materials and Methods. Results are presented as percentage of control values (mean n = 4; * indicates significant difference from control levels (P < 0.05); pooled SD = 0.8, 0.6, 1.1 and 24.4, 11.8, 12.0 for spermine levels and cell numbers respectively at 24, 96 and 168 hours). The mean spermine concentration (nmol/106 cells) in control cells at 24, 96 and 168 hr was 2.10, 1.25 and 0.76 respectively.

Table 1

Effect of I3C alone and in combination with putrescine on intracellular polyamine levels at 24, 96 and 168 hours.

Treatment

Cell no. as % Control (SD)

Putrescine (SD)

Spermidine (SD)

Spermine (SD)

24 hour

    

Control

100.0 (0.0)

0.48 (0.31)

1.62 (0.55)

2.10 (0.98)

I3C 100

89.1 (19.8)

0.31 (0.09)

1.79 (0.51)

2.25 (1.21)

I3C 175

87.9 (29.2)

0.23 (0.06)*

1.32 (0.36)

1.54 (0.19)

I3C 250

77.4 (32.7)

0.19 (0.04)*

2.17 (0.98)

2.73 (1.86)

I3C 500

54.2 (26.6)

0.14 (0.07)*

1.57 (0.60)

2.74 (1.82)

C + P20

96.9 (23.5)

0.64 (0.26)

2.17 (1.06)

2.41 (1.53)

C + P50

90.0 (42.1)

0.72 (0.27)*

2.34 (1.48)

2.59 (1.93)

I + P20

76.2 (26.3)

0.69 (0.29)

2.93 (1.57)*

3.06 (1.99)

I + P50

76.1 (35.0)

0.54 (0.16)

1.86 (0.49)

1.94 (0.65)

96 hour

    

Control

100.0 (0.0)

0.08 (0.04)

0.79 (0.30)

1.25 (0.38)

I3C 100

98.7 (8.5)

0.13 (0.09)

1.11 (0.40)

1.87 (0.47)

I3C 175

58.9 (3.8)

0.13 (0.10)

0.98 (0.29)

2.18 (0.79)*

I3C 250

24.9 (6.1)

0.15 (0.11)

0.77 (0.36)

2.03 (1.17)*

I3C 500

13.9 (6.0)

nd

0.62 (0.32)

1.34 (0.45)

C + P20

96.6 (12.4)

0.13 (0.03)

0.84 (0.15)

1.15 (0.12)

C + P50

79.2 (14.3)

0.32 (0.18)*

1.47 (0.15)*

1.98 (0.34)

I + P20

28.1 (22.6)

0.17 (0.09)

1.25 (0.23)*

2.42 (0.21)*

I + P50

17.9 (2.9)

0.11 (0.02)

0.80 (0.21)

1.54 (0.48)

168 hour

    

Control

100.0 (0.0)

0.04 (0.02)

0.46 (0.07)

0.76 (0.17)

I3C 100

104.0 (9.9)

0.03 (0.01)

0.57 (0.25)

1.22 (0.32)

I3C 175

57.1 (9.5)

0.05 (0.03)

0.62 (0.28)

1.99 (0.96)*

I3C 250

31.1 (20.2)

0.07 (0.01)

0.87 (0.54)

2.93 (0.72)*

I3C 500

4.5 (5.2)

nd

nd

nd

C + P20

107.2 (4.8)

0.03 (0.01)

0.48 (0.04)

0.83 (0.15)

C + P50

104.5 (10.1)

0.06 (0.04)

0.67 (0.10)

1.08 (0.19)

I + P20

6.0 (5.5)

nd

0.91 (0.55)

3.11 (1.59)*

I + P50

3.0 (0.7)

nd

0.90 (0.56)

2.26 (1.42)*

Cells were treated with I3C alone or in combination with putrescine, and intracellular polyamines determined as described in the Methods Section. Data shown for cell numbers are expressed as a % Control, and polyamine levels are nmol/106 cells. All values are means with SD in brackets. nd = values not determined. * indicates a value that is significantly different to the control value at that time point.

In a preliminary experiment (assays performed in duplicate) intracellular levels of GSH were determined in extracts from cells treated for either 24, 96 or 168 hours. No evidence for a decrease in GSH level was obtained with any treatment at any of the time points (data not shown).

Effect of I3C on uptake of putrescine by SW480 cells

In order to further investigate the effect of I3C on regulation of the intracellular putrescine pool, we determined putrescine uptake following treatment with I3C alone or in medium supplemented with putrescine. SW480 cells which had been treated with I3C under normal growth conditions for 24 hours exhibited a 50% decrease in the rate of putrescine uptake (Fig 9), which appeared to correlate with the decrease in intracellular putrescine levels shown in Fig 7. DFMO increased the rate of putrescine uptake 2.5-fold over control levels (Fig 9).
Figure 9

Effect of I3C on putrescine uptake in SW480 cells. Cells were treated with DMSO alone (Con), I3C or DFMO as indicated, and putrescine uptake determined as described in Materials and Methods. Results are presented as percentage of control values (n = minimum of 4) * indicates significant difference from control levels (P < 0.05).

Discussion

Upregulation of ODC has been implicated as a necessary and early step in carcinogenesis. The ability of some chemopreventive agents, such as DFMO, to inhibit ODC activity is therefore thought to be an important mechanistic contributor to their anticarcinogenicity. The results described above show for the first time that in colon cancer cells I3C decreases ODC activity and interferes with intracellular polyamine levels. However, there are intriguing differences between I3C and the classical ODC inhibitor, DFMO. Consistent with the known mechanism of action of DFMO, exogenously added putrescine antagonised growth inhibition caused by this agent. In contrast, while I3C also reduced ODC activity and decreased intracellular putrescine levels, its growth-inhibitory effect was not reversed, and in the case of the SW480 cell line, was actually increased in the presence of exogenous putrescine. This led us to conclude that in the colon tumour cells studied here, the growth inhibitory effect of I3C appeared to be independent of its ability to decrease intracellular putrescine levels. This conclusion is further supported by the observation that exogenously added putrescine restored intracellular putrescine levels of I3C-treated cells to normal. It is worthy of note, that while exogenously added putrescine can reverse growth inhibition due to impaired polyamine synthesis, it cannot reverse growth inhibition caused by altered polyamine catabolism or efflux.

It is possible that the decrease in putrescine observed at the initial time point, was not wholly due to inhibition of ODC activity or decreased uptake, but also due to the continued conversion of the diamine to spermidine, levels of which did not fall in response to I3C treatment. Putrescine levels in SW480 cells were also found to have reverted to control levels after 96 hours of treatment with I3C alone indicating that the cells overcome these initial effects of I3C observed at 24 hours. Several possibilities may account for this, including reversal of the inhibition of ODC activity and/or putrescine uptake observed after 24 hour treatment. I3C treatment of SW480 cells resulted in an accumulation of intracellular spermine over time (up to approximately 5 fold above control levels), which corresponded with a dose dependent decrease in cell number at each time point.

There are many reports in the literature detailing the cytotoxic effects of spermine [7681], although it should be noted that high concentrations of exogenous spermine were used in these studies. It is possible that the accumulation of spermine seen in response to treatment with I3C contributes to its growth-inhibitory action in this cell line. Addition of exogenous putrescine, did not prevent (nor significantly increase), the accumulation of intracellular spermine levels observed in response to treatment with I3C, which may explain, at least in part, the inability of exogenous putrescine to prevent the I3C-induced growth inhibition. Several mechanisms have been proposed for the cytotoxicity of spermine, including competition for spermidine and Mg2+ binding sites, thus preventing many of the physiological functions of spermidine and Mg2+, such as protein synthesis, as well as loss of intracellular glutathione through conjugation or spermine-induced oxidative stress, or a direct toxic effect of the spermine itself [78, 80, 81]. In preliminary experiments we found no evidence of a decrease in intracellular GSH levels following any treatment.

Seiler et al. [76] have reported a non-apoptotic mechanism of cell death in CaCo-2 cells that had accumulated high levels of spermine (more than double normal levels). In that study, exposure to 5 mM spermine caused a decrease in the population of cells in G1, and an accumulation in the G2 phase of the cell cycle [76]. In our study, at higher concentrations (≥ 250 μM), I3C caused induction of apoptosis accompanied by necrosis, but only a small increase in either was observed at the 96 hour time point with 175 μM I3C, and although we did not obtain a clear phase specific arrest with any treatment in our study, the proportion of cells in G1 decreased and the number in G2/M increased in response to I3C from 32 hours. In the combination treatment (I3C + putrescine), the number of cells in G2/M was slightly increased and the proportion of cells undergoing necrosis was significantly increased compared with I3C treatment alone. Although each of these changes appears to be small when considered in isolation, in combination they may be sufficient to account for the inhibition caused by I3C in the cell growth experiments. At 96 hr, control cells showed combined apoptosis + necrosis of less than 4%, with approximately 8% of cells in G2/M; I3C (175 μM)-treated cells showed combined apoptotic and necrotic cells of 9%, with 11% in G2/M, while of I3C + putrescine-treated cells, approximately 16% were undergoing apoptosis or necrosis, with 13% in G2/M.

The mechanism by which I3C inhibited ODC activity was not further investigated in this study, but clearly occurs at a level distinct from the direct enzyme inhibition caused by DFMO. ODC activity can be regulated via many signalling pathways, including the epidermal growth factor receptor, PI3K, and estrogen receptor pathways [4144], which are potential targets for the action of chemopreventive agents such as I3C. We have shown, for example, that I3C can inhibit the PI3K/ protein kinase B pathway in the MDA MB468 breast tumour cell line, but not in the normal derived HBL100 line [67], but this did not correlate with the ability of this agent to inhibit ODC activity in those cell lines (Howells L.M. et al. unpublished data). There are clearly multiple possible mechanisms via which I3C could exert its effect on ODC activity in these colon cell lines, including inhibition of signalling pathways such as those mentioned above.

Conclusions

Our conclusion from this work is that inhibition of ODC activity and consequent decrease in intracellular putrescine levels does not, per se, constitute a primary mechanism of action of I3C in these colon cell lines. However, perturbation of polyamine homeostasis leading to increases in intracellular spermine levels may contribute to a cytotoxic effect of the agent. The exact mechanism by which putrescine sensitised the SW480 cell line to I3C has not yet been elucidated, and the relevance of this observation to future chemopreventive strategies involving I3C remains to be determined.

List of Abbreviations

DFMO: 

Difluoromethylornithine

I3C: 

Indole-3-carbinol

ODC: 

Ornithine decarboxylase

PI3K: 

phospho-inositide 3-kinase.

Declarations

Acknowledgements

We would like to thank Drs Andrea Pfeifer and Elizabeth Offord (Nestle Ltd. Research Centre, Lausanne 26, Switzerland), for the generous gift of the HCEC cell line.

Authors’ Affiliations

(1)
Cancer Biomarkers and Prevention Group, Departments of Biochemistry & Oncology, University of Leicester
(2)
MRC Toxicology Unit
(3)
Cancer Biomarkers and Prevention Group, Department of Oncology, University of Leicester

References

  1. Jellinck PH, Forkert P-G, Riddick DS, Okey AB, Michnovicz JJ, Bradlow HL: Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation. Biochem Pharmacol. 1993, 45: 1129-1136. 10.1016/0006-2952(93)90258-X.View ArticlePubMedGoogle Scholar
  2. Bradlow HL, Michnovicz JJ, Halper M, Miller DG, Wong GYC, Osborne MP: Long-term responses of women to indole-3-carbinol or a high fiber diet. Cancer Epidemiol Biomarkers Prev. 1994, 3: 591-595.PubMedGoogle Scholar
  3. Telang NT, Katdare M, Bradlow HL, Osborne MP, Fishman J: Inhibition of proliferation and modulation of estradiol metabolism: novel mechanisms for breast cancer prevention by the phytochemical indole-3-carbinol. Proc Soc Exp Biol Med. 1997, 216: 246-252.View ArticlePubMedGoogle Scholar
  4. Wong GYC, Bradlow L, Sepkovic D, Mehl S, Mailman J, Osborne MP: Dose-ranging study of indole-3-carbinol for breast cancer prevention. J Cell Biochem Suppl. 1997, 28/29: 111-116. 10.1002/(SICI)1097-4644(1997)28/29+<111::AID-JCB12>3.0.CO;2-K.View ArticleGoogle Scholar
  5. Rosen CA, Woodson GE, Thompson JW, Hengesteg AP, Bradlow HL: Preliminary results of the use of indole-3-carbinol for recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg. 1998, 118: 810-815.View ArticlePubMedGoogle Scholar
  6. Bell MC, Crowley-Nowick P, Bradlow HL, Sepkovic DW, Schmidt-Grimminger D, Howell P, Mayeaux EJ, Tucker TE, Turbat-Herrera EA, Mathis JM: Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynaecologic Oncology. 2000, 78: 123-129. 10.1006/gyno.2000.5847.View ArticleGoogle Scholar
  7. Manson MM, Hudson EA, Ball HWL, Barrett MC, Clark HL, Judah DJ, Verschoyle RD, Neal GE: Chemoprevention of aflatoxin B1-induced carcinogenesis by indole-3-carbinol in rat liver – predicting the outcome using early biomarkers. Carcinogenesis. 1998, 19: 1829-1836. 10.1093/carcin/19.10.1829.View ArticlePubMedGoogle Scholar
  8. Tanaka T, Kojima T, Morishita Y, Mori H: Inhibitory effects of the natural products indole-3-carbinol and sinigrin during initiation and promotion phases of 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis. Jpn J Cancer Res. 1992, 83: 835-842.View ArticlePubMedGoogle Scholar
  9. Srivastava B, Shukla Y: Antitumour promoting activity of indole-3-carbinol in mouse skin carcinogenesis. Cancer Lett. 1998, 134: 91-95. 10.1016/S0304-3835(98)00247-X.View ArticlePubMedGoogle Scholar
  10. Grubbs CJ, Steele VE, Casebolt T, Juliana MM, Eto I, Whitaker LM, Dragnev KH, Kelloff GJ, Lubet RL: Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol. Anticancer Res. 1995, 15: 709-716.PubMedGoogle Scholar
  11. Xu M, Orner GA, Bailey GS, Stoner GD, Horio DT, Dashwood RH: Post-initiation effects of chlorophyllin and indole-3-carbinol in rats given 1,2-dimethylhydrazine or 2-amino-3-methyl-imidazo[4,5-f]quinoline. Carcinogenesis. 2001, 22: 309-314. 10.1093/carcin/22.2.309.View ArticlePubMedGoogle Scholar
  12. Stoner GD, Casto B, Ralston S, Roebuck B, Pereira C, Bailey G: Development of a multi-organ rat model for evaluating chemopreventive agents: efficacy of indole-3-carbinol. Carcinogenesis. 2002, 23: 265-272. 10.1093/carcin/23.2.265.View ArticlePubMedGoogle Scholar
  13. Bailey GS, Hendricks JD, Shelton DW, Nixon JE, Pawlowski N: Enhancement of carcinogenesis by the natural anti-carcinogen indole-3-carbinol. J Natl Cancer Inst. 1987, 78: 931-934.PubMedGoogle Scholar
  14. Dashwood RH, Fong AT, Williams DE, Hendricks JD, Bailey GS: Promotion of aflatoxin B1 carcinogenesis by the natural tumor modulator indole-3-carbinol: influence of dose duration, and intermittent exposure on indole-3-carbinol promotional potency. Cancer Res. 1991, 51: 2362-2365.PubMedGoogle Scholar
  15. Kim DJ, Lee KK, Han BS, Ahn B, Bae JH, Jang JJ: Biphasic modifying effect of indole-3-carbinol on diethylnitrosamine-induced preneoplastic glutathione S-transferase placental form-positive liver-cell foci in Sprague Dawley rats. Jpn J Cancer Res. 1994, 85: 578-583.View ArticlePubMedGoogle Scholar
  16. Goeger DE, Shelton DW, Hendricks JD, Bailey GS: Mechanisms of anti-carcinogenesis by indole-3-carbinol: effect on the distribution and metabolism of aflatoxin B1 in rainbow trout. Carcinogenesis. 1986, 7: 2025-2031.View ArticlePubMedGoogle Scholar
  17. Dashwood RH, Arbogast DN, Fong AT, Hendricks JD, Bailey GS: Mechanisms of anti-carcinogenesis by indole-3-carbinol: detailed in vivo DNA binding dose-response studies after dietary administration with aflatoxin B1. Carcinogenesis. 1988, 9: 427-432.View ArticlePubMedGoogle Scholar
  18. Dashwood RH, Arbogast DN, Fong AT, Pereira C, Hendricks JD, Bailey GS: Quantitative inter-relationships between aflatoxin B1 carcinogen dose, indole-3-carbinol anti-carcinogen dose, target organ DNA adduction and final tumour response. Carcinogenesis. 1989, 10: 175-181.View ArticlePubMedGoogle Scholar
  19. Stresser DM, Bailey GS, Williams DE: Indole-3-carbinol and β-naphthoflavone induction of aflatoxin B1 metabolism and cytochromes P450 associated with bioactivation and detoxification of aflatoxin B1 in the rat. Drug Metab Disp. 1994, 22: 383-391.Google Scholar
  20. Stresser M, Williams DE, McLellan LI, Harris TM, Bailey GS: Indole-3-carbinol induces a rat-liver glutathione transferase subunit (Yc2) with high activity toward aflatoxin B1 exo-epoxide – association with reduced levels of hepatic aflatoxin DNA adducts in vivo. Drug Metab Disp. 1994, 22: 392-399.Google Scholar
  21. Hayes JD, Judah DJ, McLellan LI, Neal GE: Contribution of glutathione S-transferases to the mechanisms of resistance to aflatoxin B1. Pharmacol Ther. 1991, 50: 443-472. 10.1016/0163-7258(91)90053-O.View ArticlePubMedGoogle Scholar
  22. Judah DJ, Hayes JD, Yang J-C, Lian L-Y, Roberts GCK, Farmer PB, Lamb JH, Neal GE: A novel aldehyde reductase with activity towards a metabolite of aflatoxin B1, is expressed in rat liver during carcinogenesis and following the administration of an antioxidant. Biochem J. 1993, 292: 13-18.View ArticlePubMedPubMed CentralGoogle Scholar
  23. He Y-H, Friesen MD, Ruch RJ, Schut HA: Indole-3-carbinol as a chemopreventive agent in 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) carcinogenesis: Inhibition of PhIP-DNA adduct formation, acceleration of PhIP metabolism, and induction of cytochrome P450 in female F344 rats. Food Chem Toxicol. 2000, 38: 15-23. 10.1016/S0278-6915(99)00117-9.View ArticlePubMedGoogle Scholar
  24. Pegg AE: Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res. 1988, 48: 759-774.PubMedGoogle Scholar
  25. Mohan RR, Challa A, Gupta S, Bostwick DG, Ahmad N, Agarwal R, Marengo SR, Amini SB, Paras F, MacLennan GT, Resnick MI, Mukhtar H: Overexpression of ornithine decarboxylase in prostate cancer and prostatic fluid in humans. Clin Cancer Res. 1999, 5: 143-147.PubMedGoogle Scholar
  26. Giardiello FM, Hamilton SR, Hylind LM, Yang VW, Tamez P, Casero RA: Ornithine decarboxylase and polyamines in familial adenomatous polyposis. Cancer Res. 1997, 57: 199-201.PubMedGoogle Scholar
  27. Manni A, Mauger D, Gimotty P, Badger B: Prognostic influence on survival of increased ornithine decarboxylase activity in human breast cancer. Clin Cancer Res. 1996, 2: 1901-1906.PubMedGoogle Scholar
  28. Smith MK, Goral MA, Wright JH, Matrisian LM, Morris RJ, Klein-Szanto AJP, Gilmour SK: Ornithine decarboxylase overexpression leads to increased epithelial tumor invasiveness. Cancer Res. 1997, 57: 2104-2108.PubMedGoogle Scholar
  29. O'Brien TG, Megosh LC, Gilliard G, Peralta Soler A: Ornithine decarboxylase overexpression is a sufficient condition for tumor promotion in mouse skin. Cancer Res. 1997, 57: 2630-2637.PubMedGoogle Scholar
  30. Auvinen M, Laine A, Paasinen-Sohns A, Kangas A, Kangas L, Saksela O, Anderson LC, Holtta E: Human ornithine decarboxylase-overproducing NIH3T3 cells induce rapidly growing, highly vascularised tumors in nude mice. Cancer Res. 1997, 57: 3016-3025.PubMedGoogle Scholar
  31. Auvinen M, Paasinen A, Andersson LC, Holtta E: Ornthine decarboxylase activity is critical for cell transformation. Nature. 1992, 360: 355-358. 10.1038/360355a0.View ArticlePubMedGoogle Scholar
  32. Pegg AE, Shantz LM, Coleman CS: Ornithine decarboxylase: Structure, function and translational regulation. Biochem Soc Trans. 1994, 22: 846-852.View ArticlePubMedGoogle Scholar
  33. Kubota S: Ornithine decarboxylase and cancer. Cancer J. 1998, 11: 294-297.Google Scholar
  34. Kameji T, Hayashi S-I, Hoshino K, Kakinuma Y, Igarashi K: Multiple regulation of ornithine decarboxylase in enzyme-overproducing cells. Biochem J. 1993, 289: 581-586.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Murakami Y, Matsufuji S, Hayashi S-I, Tanahashi N, Tanaka K: Degradation of ornithine decarboxylase by the 26S proteasome. Biochem Biophys Res Comm. 2000, 267: 1-6. 10.1006/bbrc.1999.1706.View ArticlePubMedGoogle Scholar
  36. Shantz LM, Pegg AE: Overproduction of ornithine decarboxylase caused by relief of translational repression is associated with neoplastic transformation. Cancer Res. 1994, 54: 2313-2316.PubMedGoogle Scholar
  37. Moshier JA, Osborne DL, Skunca M, Dosescu J, Gilbert JD, Fitzgerald MC, Polidori G, Wagner RL, Friezner Degen SJ, Luk GD, Flanagan MA: Multiple promoter elements govern expression of the human ornithine decarboxylase gene in colon carcinoma cells. Nucl Acids Res. 1992, 20: 2581-2590.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Moshier JA, Skunca M, Wu W, Boppana SM, Rauscher FJ, Dosescu J: Regulation of ornithine decarboxylase gene expression by the Wilms' tumor suppressor WT1. Nucl Acids Res. 1996, 24: 1149-1157. 10.1093/nar/24.6.1149.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Li R-S, Law GL, Seifert RA, Romaniuk PJ, Morris DR: Ornithine decarboxylase is a transcriptional target of tumor suppressor WT1. Exp Cell Res. 1999, 247: 257-266. 10.1006/excr.1998.4361.View ArticlePubMedGoogle Scholar
  40. Kumar AP, Butler AP: Transcription factor Sp3 anatagonizes activation of the ornithine decarboxylase promoter by Sp1. Nucl Acids Res. 1997, 25: 2012-2019. 10.1093/nar/25.10.2012.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Xue GZ, Zheng ZS, Chen RZ, Lloyd MB, Prystowsky JH: Phorbol 12-myristate 13-acetate inhibits epidermal growth factor signalling in human keratinocytes, leading to decreased ornithine decarboxylase activity. Biochem J. 1996, 319: 641-648.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Ishikawa T, Ichikawa Y, Tarnawski A, Fujiwara Y, Fukuda T, Arakawa T, Mitsuhashi M, Shimada H: Indomethacin interferes with EGF-induced activation of ornithine decarboxylase in gastric cancer cells. Digestion. 1998, 59: 47-52. 10.1159/000007466.View ArticlePubMedGoogle Scholar
  43. Flamigni F, Marmiroli S, Capanni C, Stefanelli C, Guarnieri C, Caldarera CM: Phoshpatidylinositol 3-kinase is required for the induction of ornithine decarboxylase in leukemia cell stimulated to growth. Biochem Biophys Res Comm. 1997, 239: 729-733. 10.1006/bbrc.1997.7543.View ArticlePubMedGoogle Scholar
  44. Huber M, Poulin R: Posttranslational cooperativity of ornithine decarboxylase induction by estrogens and peptide growth-factors in human breast-cancer cells. Mol Cell Endocrinol. 1996, 117: 211-218. 10.1016/0303-7207(95)03749-7.View ArticlePubMedGoogle Scholar
  45. Benamouzig R, Mahé S, Luengo C, Rautureau J, Tomé D: Fasting and postprandial polyamine concentrations in the human digestive lumen. Am J Clin Nutr. 1997, 65: 766-770.PubMedGoogle Scholar
  46. Bardocz S, Duguid TJ, Brown DS, Grant G, Pusztai A, White A, Ralph A: The importance of dietary polyamines in cell regeneration and growth. Br J Nutr. 1995, 73: 819-828.View ArticlePubMedGoogle Scholar
  47. Forget P, Degraeuwe PLJ, Smeets C, Deutz NEP: Fasting gastric fluid and fecal polyamine concentrations in premature infants. J Ped Gastroenterol Nutr. 1997, 24: 389-392. 10.1097/00005176-199704000-00006.View ArticleGoogle Scholar
  48. Forget P, Sinaasappel M, Bouquet J, Deutz NEP, Smeets C: Fecal polyamine concentration in children with and without nutrient malabsorption. J Ped Gastroenterol Nutr. 1997, 24: 285-288. 10.1097/00005176-199703000-00010.View ArticleGoogle Scholar
  49. Noack J, Dongowski G, Hartmann L, Blaut M: The human gut bacteria Bacteroides thetaiotaomicrom and Fusobacterium varium produce putrescine and spermidine in cecum of pectin-fed gnotobiotic rats. J Nutr. 2000, 130: 1225-1231.PubMedGoogle Scholar
  50. Seiler N, Sarhan S, Grauffel C, Jones R, Knödgen B, Moulinoux JP: Endogenous and exogenous polyamines in support of tumor growth. Cancer Res. 1990, 50: 5077-5083.PubMedGoogle Scholar
  51. Meyskens FL, Gerner EW: Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res. 1999, 5: 945-951.PubMedGoogle Scholar
  52. Lieberman R, Nelson WG, Sakr WA, Meyskens FL, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM: Executive summary of the National Cancer Institute Workshop: Highlights and recommendations. Urology. 2001, 57: 4-27. 10.1016/S0090-4295(00)00931-6.View ArticlePubMedGoogle Scholar
  53. Einspahr JG, Nelson MA, Saboda K, Warneke J, Bowden GT, Alberts DS: Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer. Clin Cancer Res. 2002, 8: 149-155.PubMedGoogle Scholar
  54. Gupta S, Ahmad N, Marengo SR, MacLennan GT, Greenberg NM, Mukhtar H: Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice. Cancer Res. 2000, 60: 5125-5133.PubMedGoogle Scholar
  55. Love RR, Jacoby R, Newton MA, Tutsch KD, Simon K, Pomplun M, Verma AK: A randomized, placebo-controlled trial of low-dose α-difluoromethylornithine in individuals at risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev. 1998, 7: 989-992.PubMedGoogle Scholar
  56. Fabian CJ, Kimler BF, Brady DA, Mayo MS, Chang CHJ, Ferraro JA, Zalles CM, Stanton AL, Masood S, Grizzle WE, Boyd NF, Arneson DW, Johnson KA: A phase II breast cancer chemoprevention trail of oral alpha-difluoromethylornithine: Breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res. 2002, 8: 3105-3117.PubMedGoogle Scholar
  57. O'Shaughnessy JA, Demers LM, Jones SE, Arseneau J, Khandelwal P, George T, Gersh R, Mauger D, Manni A: alpha-difluoromethylornithine as treatment for metastatic breast cancer patients. Clin Cancer Res. 1999, 5: 3438-3444.PubMedGoogle Scholar
  58. Meyskens FL, Gerner EW, Emerson S, Pelot D, Durbin T, Doyle K, Lagerberg W: Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. J Natl Cancer Inst. 1998, 90: 1212-1218. 10.1093/jnci/90.16.1212.View ArticlePubMedGoogle Scholar
  59. Hudson EA, Dinh PA, Kokubun T, Simmonds MSJ, Gescher A: Characterization of potentially chemopreventive phenols in extracts of brown rice that inhibit the growth of human breast and colon cancer cells. Cancer Epidemiol Biomarkers Prev. 2000, 9: 1163-1170.PubMedGoogle Scholar
  60. Plummer SM, Holloway KA, Manson MM, Munks RJL, Kaptein A, Farrow S, Howells L: Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kB activation via the NIK/IKK signalling complex. Oncogene. 1999, 18: 6013-6020. 10.1038/sj.onc.1202980.View ArticlePubMedGoogle Scholar
  61. Seiler N, Delcros JG, Vaultier M, Le Roch N, Havouis R, Douaud F, Moulinoux JP: Bis(7-amino-4-azaheptyl)dimethylsilane and Bis(7-ethylamino-4-azaheptyl)dimethylsilane: Inhibition of tumor growth in vitro and in vivo. Cancer Res. 1996, 56: 5624-5630.PubMedGoogle Scholar
  62. Bergeron RJ, Hawthorne TR, Vinson JR, Beck DE, Ingeno MJ: Role of the methylene backbone in the antiproliferative activity of polyamine analogues on L1210 cells. Cancer Res. 1989, 49: 2959-2964.PubMedGoogle Scholar
  63. Aboul-Enein HY, Al-Duraibi IA: Separation of several free polyamines and their acetylated derivatives by ion-pair reversed-phase high performance liquid chromatography. Biomed Chrom. 1998, 12: 291-293. 10.1002/(SICI)1099-0801(199809/10)12:5<291::AID-BMC749>3.0.CO;2-4.View ArticleGoogle Scholar
  64. Baker MA, Cerniglia GJ, Zaman A: Microtiter plate assay for the measurement of glutathione and glutathione disulfide in large numbers of biological samples. Anal Biochem. 1990, 190: 360-365.View ArticlePubMedGoogle Scholar
  65. Snedecor GW, Cochran WG: Analysis of Variance. In: Statistical Methods. Edited by: Snedecor GW, Cochran WG. 1980, Ames: The Iowa State University Press, 215-237. 7Google Scholar
  66. Afifi AA, Azen SP: The Analysis of Variance. In: Statistical Analysis A Computer Oriented Approach. Edited by: Afifi AA, Azen SP. 1979, London: Academic Press, Inc, 198-273. 2Google Scholar
  67. Howells LM, Gallacher-Horley B, Houghton CE, Manson MM, Hudson EA: Indole-3-carbinol Inhibits Protein Kinase B/Akt and Induces Apoptosis in the Human Breast Tumor Cell Line MDA MB468 but not in the Nontumorigenic HBL100 Line. Mol Cancer Ther. 2002, 1: 1161-1172.PubMedGoogle Scholar
  68. Ge X, Fares FA, Yannai S: Induction of apoptosis in MCF-7 cells by indole-3-carbinol is independent of p53 and Bax. Anticancer Res. 1999, 19: 3199-3204.PubMedGoogle Scholar
  69. Meng QH, Goldberg ID, Rosen EM, Fan SJ: Inhibitory effects of indole-3-carbinol on invasion and migration in human breast cancer cells. Breast Cancer Res Treat. 2000, 63: 147-152. 10.1023/A:1006495824158.View ArticlePubMedGoogle Scholar
  70. Rahman KMW, Aranha O, Glazyrin A, Chinni SR, Sarkar FH: Translocation of Bax to mitochondria induces apoptotic cell death in Indole-3-carbinol (I3C) treated breast cancer cells. Oncogene. 2000, 19: 5764-5771. 10.1038/sj.onc.1203735.View ArticlePubMedGoogle Scholar
  71. Bonnesen C, Eggleston IM, Hayes JD: Dietary indoles and isothiocyanates that are generated from cruciferous vegetables can both stimulate apoptosis and confer protection against DNA damage in human colon cancer cell lines. Cancer Res. 2001, 61: 6120-6130.PubMedGoogle Scholar
  72. Gamet L, Cazenave Y, Trocheris V, Denis-Pouxviel C, Murat J-C: Involvement of ornithine decarboxylase in the control of proliferation of the HT29 human colon cancer cell line. Effect of vasoactive intestinal peptide on enzyme activity. Int J Cancer. 1991, 47: 633-638.View ArticlePubMedGoogle Scholar
  73. Ray RM, Zimmerman BJ, McCormack SA, Patel TB, Johnson LR: Polyamine depletion arrests cell cycle and induces inhibitors p21(Waf1/Cip1), p27(Kip1), and p53 in IEC-6 cells. Am J Physiol. 1999, 276: C684-C691.PubMedGoogle Scholar
  74. Nemoto T, Kamei S, Seyama Y, Kubota S: p53 independent G(1) arrest induced by DL-alpha-difluoromethylornithine. Biochem Biophys Res Comm. 2001, 280: 848-854. 10.1006/bbrc.2000.4227.View ArticlePubMedGoogle Scholar
  75. Ray RM, McCormack SA, Johnson LR: Polyamine depletion arrests growth of IEC-6 and CaCo-2 cells by different mechanisms. Am J Physiol. 2001, 281: G37-G43.Google Scholar
  76. Seiler N, Duranton B, Gosse F, Raul F: Spermine cytotoxicity to human colon carcinoma-derived cells (CaCo-2). Cell Biol Tox. 2000, 16: 117-130. 10.1023/A:1007642126765.View ArticleGoogle Scholar
  77. Tipnis UR, He G-Y: Mechanism of polyamine toxicity in cultured cardiac myocytes. Toxicol in Vitro. 1998, 12: 233-240. 10.1016/S0887-2333(97)00116-1.View ArticlePubMedGoogle Scholar
  78. He Y, Kashiwagi K, Fukuchi J-I, Terao K, Shirahata A, Igarashi K: Correlation between the inhibition of cell growth by accumulated polyamines and the decrease of magnesium and ATP. Eur J Biochem. 1993, 217: 89-96.View ArticlePubMedGoogle Scholar
  79. Brunton VG, Grant MH, Wallace HM: Spermine toxicity in BHK-21/C13 cells in the presence of bovine serum: the effect of aminoguanidine. Toxicol in Vitro. 1994, 8: 337-341. 10.1016/0887-2333(94)90154-6.View ArticlePubMedGoogle Scholar
  80. Brunton VG, Grant MH, Wallace HM: Spermine toxicity and glutathione depletion in BHK-21/C13 cells. Biochem Pharmacol. 1990, 40: 1893-1900. 10.1016/0006-2952(90)90371-Q.View ArticlePubMedGoogle Scholar
  81. Brunton VG, Grant MH, Wallace HM: Mechanisms of spermine toxicity in baby-hamster kidney (BHK) cells. Biochem J. 1991, 280: 193-198.View ArticlePubMedPubMed CentralGoogle Scholar
  82. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/3/2/prepub

Copyright

© Hudson et al; licensee BioMed Central Ltd. 2003

This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Advertisement